WeTrade Group has entered into a strategic partnership with Jiqing Biomedical Technology to offer monkeypox testing.

Aiming to develop domestic and international markets, the companies will produce and provide exclusive sales channels around the world for monkeypox test kits and antigen tests.

Monkeypox has been declared a public health emergency in the United States due to its rapid spread.

Jiqing bioresearch and development team has developed two monkeypox virus detection kits, antigen test (colloidal gold technique) and nucleic acid test (RT-LAMP), aiming to to help prevent and control the epidemic.

The technical service provider WeTrade offers software as a service (SAAS) and has independently developed the intelligent cloud system (YCloud) for micro-enterprises.

Using big data technology and analytics, YCloud strengthens marketing relationships and user CPS commission profit management.

Under the collaboration agreement with Jiqing, WeTrade will provide next-generation technology, from computing technology and big data accumulation in YCloud, to support the medical industry.

The company will also build a SaaS platform and a data platform to help rethink medical industry models.

WeTrade CEO Pijun Liu said, “The Covid pandemic has caused enormous harm to the public, and monkeypox has had a significant impact on people in several countries.

“To solve the problem, we look forward to cooperation between us and Jiqing.

“We hope to bring the two monkeypox virus test kits to market as soon as possible through the empowerment of technology, to help prevent and control the virus and reduce harm to the public worldwide.”

Related companies